Definium Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-183.8M | $-108.7M | $-95.7M | $-56.8M | $-93.0M | $-33.9M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — |
| Amortization | $0 | $527.0K | $3.2M | $3.2M | $2.6M | $0 |
| Stock-Based Compensation | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-131.6M | $-79.1M | $-64.4M | $-50.1M | $-45.8M | $-23.6M |
| Investing Activities | ||||||
| Capital Expenditures | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | $297.0K | — |
| Net Cash from Investing Activities | $-151.6M | $0 | — | — | $-297.0K | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $267.3M | $253.2M | $21.8M | $59.1M | $98.8M | $96.7M |
| Net Change in Cash | $-15.9M | $174.0M | $-42.4M | $8.6M | $53.4M | $73.4M |
| Free Cash Flow | — | — | — | — | — | — |